GHK-Cu offers a "Barrier-First" alternative
These effects typically resolve within 24 hours and require no treatment
Sourcing, purity, and sterile administration all affect safety, and unsupervised or gray-market peptides carry meaningful risk
A., Seljeflot, I., & Hanssen, K
In some embodiments is an enhanced viscosity formulation, comprising from about 0.1 mM and about 100 mM of an active agent, a pharmaceutically acceptable viscosity enhancer or viscosity modulating agent, and water for injection, the concentration of the viscosity enhancer or viscosity modulating agent in the water being sufficient to provide an enhanced viscosity formulation with a final viscosity from about 100 to about 100,000 cP